Early assessment of antibodies decline in Chagas patients following treatment using a serological multiplex immunoassay.

Autor: Saade U; InfYnity Biomarkers, Lyon, France.; Swiss Tropical and Public Health Institute, Department of Medical Parasitology and Infection Biology, 4123, Allschwil, Switzerland.; University of Basel, 4001, Basel, Switzerland., de Boer J; Department of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium., Scandale I; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland., Altcheh J; Parasitology Service, Hospital de Niños 'Ricardo Gutierrez' and Instituto Multidisciplinario de Investigacion en Patologias Pediatricas (IMIPP)-CONICET-GCBA, Buenos Aires, Argentina., Pottel H; Department of Public Health and Primary Care, KU Leuven Campus Kulak Kortrijk, Kortrijk, Belgium., Chatelain E; Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland. echatelain@dndi.org., Zrein M; InfYnity Biomarkers, Lyon, France. mzrein@infynity-biomarkers.com.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2024 Dec 03; Vol. 15 (1), pp. 10530. Date of Electronic Publication: 2024 Dec 03.
DOI: 10.1038/s41467-024-54910-x
Abstrakt: Chagas disease following infection with Trypanosoma cruzi is a major public health issue, with the disease spreading beyond endemic regions and becoming more global due to the migration of infected individuals. The currently available anti-parasitic drugs, nifurtimox and benznidazole, remain insufficiently evaluated for their efficacy in adult patients. A key challenge is the lack of markers for parasitological cure, which also precludes the development of new treatments. Consequently, there is a critical need for a practical method to assess drug performance within a short timeframe. In this retrospective analysis of the phase 2 randomized controlled BENDITA trial (ClinicalTrials.gov: NCT03378661), we report the potential of a serological multiplex method (MultiCruzi), combined with advanced statistical analytical methods, to measure the response to anti-parasitic treatment of adult Chagas patients. Applying this approach to serum samples from adult patients in the indeterminate chronic stage of Chagas disease, treated with different benznidazole regimens and combinations, we predict treatment efficacy after just 6 months of follow-up, in sharp contrast to data obtained with conventional and recombinant T. cruzi ELISA tests. The obtained results are also compared with the PCR data. We propose integrating MultiCruzi as a serological method endpoint in proof-of-concept clinical trials for Chagas disease.
Competing Interests: Competing interests: U.S. and M.Z. are employed by InfYnity Biomarkers. All other authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: